Martin Shkreli will be responsible for $10.4 million in financial losses when he faces sentencing for defrauding hedge fund investors on March 9, 2018.
French company DBV Technologies said its Viaskin Milk product yielded successful results in a Phase II trial for patients suffering from IgE-mediated cow’s milk protein allergy.
Roche said the European Commission approved the Swiss Group’s drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.
Aldeyra signed a collaboration research deal with Johnson & Johnson’s Janssen Research & Development to develop drugs that sequester pro-inflammatory aldehyde mediators.
A coalition of 20 U.S. states sued the federal government over Obamacare, claiming the law was no longer constitutional.
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending a label variation for Neulasta (pegfilgrastim) to include the Neulasta Onpro Kit.
Adscend Media will be hosting a webinar designed to help advertisers combat ad fraud. Titled, “Fighting Back Against Ad Fraud,” the hour-long webinar will provide strategies for desktop and mobile advertisers to minimize invalid traffic, using historical data from the Adscend platform. The free event also features a question and answer session with Adscend Media CEO Fehzan Ali, as well details on the company’s pioneering Total Fraud Defense technology.
With the 2018 theme #PressForProgress, a Panel of HBA leaders was assembled to share practical examples of how they have leveraged their HBA experience — what they have learned and the relationships they have developed — to move the needle in their own careers and enhance their organization’s performance.
Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen.
U.S. regulators approved expanded use of Eli Lilly and Co.’s Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease.